A study in Scientific Reports investigates the association between proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RA) use on chronic kidney disease (CKD) risk.
Mirati’s lung cancer treatment gains EMA CHMP’s positive opinion
Krazati is being analysed as a single agent and with other anti-cancer treatments for advanced KRASG12C-mutated solid tumours, such as NSCLC. Credit: 15Studio / Shutterstock.com.